{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:34:22Z","timestamp":1747204462904,"version":"3.40.5"},"posted":{"date-parts":[[2023,2,7]]},"group-title":"In Review","reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,1,30]]},"abstract":"<title>Abstract<\/title><p>There is paucity of data regarding outcomes of children, adolescents and young adults (CAYA) patients with non-Hodgkin lymphoma (NHL) undergoing autologous hematopoietic stem cell transplantation (ASCT). We analyzed 222 patients aged 0\u201339 years undergoing first ASCT for NHL between 2000 and 2020. The most common histological subtypes were DLBCL (44%), T-NHL (19%) and PMBCL (19%). Younger patients (age\u2009\u2264\u200925) had lower incidence of DLBCL and higher incidence of PMBCL and T-NHL compared to older patients (&gt;\u200925 years) (P\u2009=\u20090.02). None of the younger patients had DH)\/DE DLBCL, as compared to 14 patients in the older group (18%, P\u2009=\u20090.07). Younger patients had numerically better 15-year post-transplant PFS (67% vs. 54%) and OS (71% vs. 62%) compared to older patients, without statistically significant differences (P\u2009=\u20090.19 and P\u2009=\u20090.24, respectively). In MVA, not achieving a CR prior to ASCT was independently predictive of worse PFS (P\u2009&lt;\u20090.0001). DH\/DE status was an independent adverse predictor of PFS in MVA (HR 5.8, p\u2009=\u20090.03). 10 patients(4.5%) (all aged\u2009&gt;\u200925 years) developed SPM Patients aged\u2009\u2264\u200925 years presented a distinct NHL histology as compared to older CAYA patients. Disease status at ASCT was predictive of both PFS and OS. DH\/DE status was an adverse predictor of PFS.<\/p>","DOI":"10.21203\/rs.3.rs-2531406\/v1","type":"posted-content","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T20:58:19Z","timestamp":1675803499000},"source":"Crossref","is-referenced-by-count":0,"title":["Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed\/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant"],"prefix":"10.21203","author":[{"given":"Yago","family":"Nieto","sequence":"first","affiliation":[{"name":"MD Anderson Cancer Center, University of Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oren","family":"Pasvolsky","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4534-2042","authenticated-orcid":false,"given":"Roland","family":"Bassett","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7295-0978","authenticated-orcid":false,"given":"Sassine","family":"Ghanem","sequence":"additional","affiliation":[{"name":"Warren Alpert School of Medicine at Brown University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branko","family":"Cuglievan","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priti","family":"Tewari","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHITRA","family":"HOSING","sequence":"additional","affiliation":[{"name":"M.D. ANDERSON CANCER CENTER"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samer","family":"Sr","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Ramdial","sequence":"additional","affiliation":[{"name":"M D Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2649-9674","authenticated-orcid":false,"given":"Kris","family":"Mahadeo","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3731-608X","authenticated-orcid":false,"given":"Sajad","family":"Khazal","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demetrios","family":"Petropoulos","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-2224","authenticated-orcid":false,"given":"Uday","family":"Popat","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2876-2886","authenticated-orcid":false,"given":"Muzaffar","family":"Qazilbash","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8607-9404","authenticated-orcid":false,"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-5037","authenticated-orcid":false,"given":"Richard","family":"Champlin","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Shpall","sequence":"additional","affiliation":[{"name":"M.D. Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamapediatrics.2015.4689","article-title":"Cancer in Adolescents and Young Adults: A Narrative Review of the Current Status and a View of the Future","volume":"170","author":"Barr RD","year":"2016","unstructured":"Barr RD, Ferrari A, Ries L, Whelan J, Bleyer WA. Cancer in Adolescents and Young Adults: A Narrative Review of the Current Status and a View of the Future. JAMA Pediatr. 2016;170(5):495\u2013501.","journal-title":"JAMA Pediatr"},{"issue":"8","key":"ref2","doi-asserted-by":"crossref","first-page":"e27073","DOI":"10.1002\/pbc.27073","article-title":"NHL in adolescents and young adults: A unique population","volume":"65","author":"Hochberg J","year":"2018","unstructured":"Hochberg J, Flower A, Brugieres L, Cairo MS. NHL in adolescents and young adults: A unique population. Pediatr Blood Cancer. 2018;65(8):e27073.","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/PAS.0b013e3181bb9a18","article-title":"Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome","volume":"33","author":"Gualco G","year":"2009","unstructured":"Gualco G, Weiss LM, Harrington WJ, Jr., Bacchi CE. Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome. Am J Surg Pathol. 2009;33(12):1815\u201322.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/pbc.21619","article-title":"Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group","volume":"51","author":"Miles RR","year":"2008","unstructured":"Miles RR, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe MJ, et al. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group. Pediatr Blood Cancer. 2008;51(3):369\u201374.","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2005-10-4213","article-title":"Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial","volume":"107","author":"Oschlies I","year":"2006","unstructured":"Oschlies I, Klapper W, Zimmermann M, Krams M, Wacker HH, Burkhardt B, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood. 2006;107(10):4047\u201352.","journal-title":"Blood"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"e11-e9","DOI":"10.1016\/j.bbmt.2018.09.011","article-title":"Unique Challenges of Hematopoietic Cell Transplantation in Adolescent and Young Adults with Hematologic Malignancies","volume":"24","author":"Mehta PA","year":"2018","unstructured":"Mehta PA, Rotz SJ, Majhail NS. Unique Challenges of Hematopoietic Cell Transplantation in Adolescent and Young Adults with Hematologic Malignancies. Biol Blood Marrow Transplant. 2018;24(12):e11-e9.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00432-020-03419-z","article-title":"Clinical, social, and psycho-oncological needs of adolescents and young adults (AYA) versus older patients following hematopoietic stem cell transplantation","volume":"147","author":"Pulewka K","year":"2021","unstructured":"Pulewka K, Strauss B, Hochhaus A, Hilgendorf I. Clinical, social, and psycho-oncological needs of adolescents and young adults (AYA) versus older patients following hematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2021;147(4):1239\u201346.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/pon.5577","article-title":"Measuring health-related quality of life in adolescent and young adult cancer survivors with the National Institutes of Health Patient-Reported Outcomes Measurement Information System((R)): Comparing adolescent, emerging adult, and young adult survivor perspectives","volume":"30","author":"Siembida EJ","year":"2021","unstructured":"Siembida EJ, Reeve BB, Zebrack BJ, Snyder MA, Salsman JM. Measuring health-related quality of life in adolescent and young adult cancer survivors with the National Institutes of Health Patient-Reported Outcomes Measurement Information System((R)): Comparing adolescent, emerging adult, and young adult survivor perspectives. Psychooncology. 2021;30(3):303\u201311.","journal-title":"Psychooncology"},{"year":"2014","author":"Barrington SF","key":"ref9","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048-58."},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson BD","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386.","journal-title":"J Clin Oncol"},{"issue":"20","key":"ref11","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow SH","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"102044","DOI":"10.1016\/j.canep.2021.102044","article-title":"Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors","volume":"75","author":"Berkman AM","year":"2021","unstructured":"Berkman AM, Andersen CR, Puthenpura V, Livingston JA, Ahmed S, Cuglievan B, et al. Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors. Cancer Epidemiol. 2021;75:102044.","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12185-016-2120-1","article-title":"Outcome differences between children and adolescents and young adults with non-Hodgkin lymphoma following stem cell transplantation","volume":"105","author":"Kobayashi R","year":"2017","unstructured":"Kobayashi R, Mitsui T, Fujita N, Osumi T, Aoki T, Aoki K, et al. Outcome differences between children and adolescents and young adults with non-Hodgkin lymphoma following stem cell transplantation. Int J Hematol. 2017;105(3):369\u201376.","journal-title":"Int J Hematol"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092075","article-title":"Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations","volume":"13","author":"Burkhardt B","year":"2021","unstructured":"Burkhardt B, Taj M, Garnier N, Minard-Colin V, Hazar V, Mellgren K, et al. Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations. Cancers (Basel). 2021;13(9).","journal-title":"Cancers (Basel)"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/pbc.24722","article-title":"Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation","volume":"60","author":"Giulino-Roth L","year":"2013","unstructured":"Giulino-Roth L, Ricafort R, Kernan NA, Small TN, Trippett TM, Steinherz PG, et al. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. Pediatr Blood Cancer. 2013;60(12):2018\u201324.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2009.09.021","article-title":"Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents","volume":"16","author":"Gross TG","year":"2010","unstructured":"Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2010;16(2):223\u201330.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2010.08162.x","article-title":"Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy","volume":"150","author":"Dickinson M","year":"2010","unstructured":"Dickinson M, Hoyt R, Roberts AW, Grigg A, Seymour JF, Prince HM, et al. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol. 2010;150(1):39\u201345.","journal-title":"Br J Haematol"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.bbmt.2015.01.013","article-title":"Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease","volume":"21","author":"Beitinjaneh A","year":"2015","unstructured":"Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, et al. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant. 2015;21(5):855\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"28","key":"ref19","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green TM","year":"2012","unstructured":"Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.2016.68.2740","article-title":"Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation","volume":"35","author":"Herrera AF","year":"2017","unstructured":"Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, et al. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol. 2017;35(1):24\u201331.","journal-title":"J Clin Oncol"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/10428190902756578","article-title":"Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma","volume":"50","author":"Seshadri T","year":"2009","unstructured":"Seshadri T, Pintilie M, Kuruvilla J, Keating A, Tsang R, Zadeh S, et al. Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2009;50(3):380\u20136.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/bmt.2012.166","article-title":"Second malignancies after autologous hematopoietic cell transplantation in children","volume":"48","author":"Danner-Koptik KE","year":"2013","unstructured":"Danner-Koptik KE, Majhail NS, Brazauskas R, Wang Z, Buchbinder D, Cahn JY, et al. Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplant. 2013;48(3):363\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41375-020-0841-x","article-title":"Second malignant neoplasms after treatment of non-Hodgkin's lymphoma-a retrospective multinational study of 189 children and adolescents","volume":"35","author":"Attarbaschi A","year":"2021","unstructured":"Attarbaschi A, Carraro E, Ronceray L, Andres M, Barzilai-Birenboim S, Bomken S, et al. Second malignant neoplasms after treatment of non-Hodgkin's lymphoma-a retrospective multinational study of 189 children and adolescents. Leukemia. 2021;35(2):534\u201349.","journal-title":"Leukemia"},{"issue":"10343","key":"ref24","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar M","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294\u2013308.","journal-title":"Lancet"},{"issue":"7","key":"ref25","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke FL","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. New Engl J Med. 2022;386(7):640\u201354.","journal-title":"New Engl J Med"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2531406\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2531406\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T11:36:36Z","timestamp":1701862596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2531406\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":25,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-2531406\/v1","relation":{},"subject":[],"published":{"date-parts":[[2023,2,7]]},"subtype":"preprint"}}